Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1626 1673 1693
This examiner grants 52% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18542778 | CELLULOSE PARTICLES AND METHOD FOR PRODUCING CELLULOSE PARTICLES | Non-Final OA | FUJIFILM Business Innovation Corp. |
| 18563804 | MACROLIDE COMPOUNDS | Non-Final OA | VANDERBILT UNIVERSITY |
| 18378404 | OMEGA-3 FATTY ACID AND VITAMIN D LEVELS TO IDENTIFY AND ATTENUATE COGNITIVE AGING IN INDIVIDUALS | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18423681 | NANOHYBRID CHITOSAN COMPOSITE-BASED CORROSION INHIBITOR | Non-Final OA | Imam Abdulrahman Bin Faisal University |
| 18530106 | PHARMACEUTICAL COMPOSITION FOR ENHANCING IMMUNITY OR ANTI-CANCER ACTIVITY INCLUDING EXTRACT OF PSEUDOLYSIMACHION NAKAIANUM (OHWI) T.YAMAZ AS ACTIVE INGREDIENT | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18471821 | COMPOSITION FOR IMPROVING THE SOLUBILITY OF POORLY SOLUBLE SUBSTANCES, COMPLEX FORMULATION AND LIQUID FORMULATION OF AN ACTIVE INGREDIENT | Final Rejection | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE |
| 17785251 | METHOD FOR ENRICHING VESICULAR RNA | Final Rejection | QIAGEN GmbH |
| 18548711 | PURIFICATION METHODS FOR OLIGOMERIC COMPOUNDS | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 18284614 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | Non-Final OA | Sinai Health System |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy